Robin Harper Cowie has been with Biodesix since March 2011 and has served as Chief Financial Officer since April 2017. She brings deep experience in healthcare finance, reimbursement strategy, health economics, operations, and public company leadership, along with a long history of helping innovative diagnostic technologies achieve broad market adoption.
As Chief Financial Officer, Ms. Cowie provides strategic, operational, and financial leadership across the organization and partners closely with the Chief Executive Officer and Board of Directors in developing and executing the Company’s growth strategy. Her responsibilities have included oversight of finance, accounting, investor relations, legal affairs, government affairs, information technology, health economics and outcomes research, customer operations, reimbursement, billing, and healthcare policy initiatives. She has also played a key leadership role in capital markets activities, financial planning and controls, financial reporting, risk management, and the Company’s successful transition to a publicly traded organization.
Throughout her tenure at Biodesix, Ms. Cowie has led initiatives involving reimbursement policy, market access, pricing strategy, payer engagement, and health economics evidence generation. She has worked extensively with Medicare, commercial insurers, healthcare systems, and accountable care organizations to improve patient access to innovative diagnostic technologies and precision medicine solutions. Her experience spans coverage and coding strategy, payer negotiations, pricing, reimbursement policy, and evidence-development programs supporting adoption of novel diagnostics.
In addition to her financial leadership responsibilities, Ms. Cowie has helped scale Biodesix operational infrastructure as the Company evolved from an early-stage diagnostics organization into a publicly traded precision diagnostics company. Her experience includes supporting high-complexity laboratory operations, laboratory workflow optimization and automation initiatives, commercialization programs, information technology systems, customer operations, supply chain coordination, and strategic partnerships. She has led intellectual property, technology transfer, licensing, and patent-related activities supporting development and commercialization of diagnostic products.
Prior to becoming Chief Financial Officer, Ms. Cowie served in several leadership roles at Biodesix, including Vice President of Finance, Vice President of Reimbursement & Health Economics, Senior Director of Reimbursement, and Director of Reimbursement. Before joining Biodesix, she held leadership positions in payer and government relations at Precision Therapeutics, Inc. Her background also includes laboratory management and research at the University of Pittsburgh Medical Center focused on migraine, epilepsy, and ALS.
Ms. Cowie has been widely recognized for her leadership in corporate finance and strategic execution, including The Healthcare Technology Report’s Top Women Leaders in Healthcare Technology, receiving the Denver Business Journal CFO Award, and being recognized as an Outstanding Women in Business by the Denver Business Journal.
Ms. Cowie currently serves as Vice Chair of the Board for the Colorado BioScience Association (CBSA). Formerly serving as Secretary, she has been a CBSA Board member since 2023. Ms. Cowie earned a Bachelor of Science in Molecular Biology from the University of Pittsburgh and a Master of Business Administration in Finance from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh.
